Viatris Total Non-Operating Income/Expense 2010-2024 | VTRS

Viatris annual/quarterly total non-operating income/expense history and growth rate from 2010 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
  • Viatris total non-operating income/expense for the quarter ending September 30, 2024 was $-0.135B, a 173.54% increase year-over-year.
  • Viatris total non-operating income/expense for the twelve months ending September 30, 2024 was $-0.687B, a 145.58% decline year-over-year.
  • Viatris annual total non-operating income/expense for 2023 was $-0.563B, a 147.01% decline from 2022.
  • Viatris annual total non-operating income/expense for 2022 was $1.198B, a 290.09% decline from 2021.
  • Viatris annual total non-operating income/expense for 2021 was $-0.63B, a 23.51% increase from 2020.
Viatris Annual Total Non-Operating Income/Expense
(Millions of US $)
2023 $-563
2022 $1,198
2021 $-630
2020 $-510
2019 $-561
2018 $-607
2017 $-534
2016 $-578
2015 $-546
2014 $-378
2013 $-388
2012 $-305
2011 $-351
2010 $-366
2009 $-296
Viatris Quarterly Total Non-Operating Income/Expense
(Millions of US $)
2024-09-30 $-135
2024-06-30 $-152
2024-03-31 $1
2023-12-31 $-401
2023-09-30 $-50
2023-06-30 $-36
2023-03-31 $-77
2022-12-31 $1,670
2022-09-30 $-133
2022-06-30 $-159
2022-03-31 $-180
2021-12-31 $-126
2021-09-30 $-158
2021-06-30 $-171
2021-03-31 $-175
2020-12-31 $-132
2020-09-30 $-110
2020-06-30 $-114
2020-03-31 $-154
2019-12-31 $-137
2019-09-30 $-138
2019-06-30 $-148
2019-03-31 $-139
2018-12-31 $-156
2018-09-30 $-146
2018-06-30 $-160
2018-03-31 $-145
2017-12-31 $-92
2017-09-30 $-137
2017-06-30 $-149
2017-03-31 $-156
2016-12-31 $-89
2016-09-30 $-195
2016-06-30 $-208
2016-03-31 $-87
2015-12-31 $-206
2015-09-30 $-146
2015-06-30 $-96
2015-03-31 $-98
2014-12-31 $-120
2014-09-30 $-82
2014-06-30 $-88
2014-03-31 $-87
2013-12-31 $-80
2013-09-30 $-145
2013-06-30 $-89
2013-03-31 $-75
2012-12-31 $-72
2012-09-30 $-70
2012-06-30 $-71
2012-03-31 $-92
2011-12-31 $-119
2011-09-30 $-74
2011-06-30 $-77
2011-03-31 $-81
2010-12-31 $-96
2010-09-30 $-103
2010-06-30 $-94
2010-03-31 $-73
2009-12-31 $-86
2009-09-30 $-77
2009-06-30 $-53
2009-03-31 $-81
Sector Industry Market Cap Revenue
Medical Medical Services $15.576B $15.427B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $91.424B 11.34
Cencora (COR) United States $47.484B 17.51
DiDi Global (DIDIY) China $23.330B 0.00
Natera (NTRA) United States $21.401B 0.00
ICON (ICLR) Ireland $16.136B 14.37
Avantor (AVTR) United States $13.422B 20.12
Revvity (RVTY) United States $13.376B 23.24
CochLear (CHEOY) Australia $12.844B 0.00
BioMerieux (BMXMF) France $12.666B 0.00
Solventum (SOLV) United States $11.583B 0.00
Medpace Holdings (MEDP) United States $9.789B 27.58
Doximity (DOCS) United States $9.620B 56.63
Charles River Laboratories (CRL) United States $9.516B 18.39
HealthEquity (HQY) United States $8.966B 48.66
Sonic Healthcare (SKHHY) Australia $8.758B 0.00
Bausch + Lomb (BLCO) Canada $6.885B 32.05
Life Times (LTH) United States $5.085B 33.66
Sotera Health (SHC) United States $3.855B 20.62
Organon (OGN) United States $3.757B 3.79
BrightSpring Health Services (BTSG) United States $3.247B 69.07
Surgery Partners (SGRY) United States $2.892B 32.97
PACS (PACS) United States $2.606B 0.00
Concentras Parent (CON) United States $2.581B 0.00
Ardent Health Partners (ARDT) United States $2.375B 0.00
Premier (PINC) United States $2.143B 11.15
Alignment Healthcare (ALHC) United States $2.126B 0.00
Ryman Healthcare (RYHTY) New Zealand $2.036B 0.00
GeneDx Holdings (WGS) United States $1.952B 0.00
GoodRx Holdings (GDRX) United States $1.616B 42.40
Teladoc Health (TDOC) United States $1.537B 0.00
Pediatrix Medical (MD) United States $1.255B 12.28
CareDx (CDNA) United States $1.183B 0.00
Progyny (PGNY) United States $1.164B 23.57
Establishment Labs Holdings (ESTA) $1.050B 0.00
AMN Healthcare Services Inc (AMN) United States $0.954B 6.46
QDM (QDMI) Hong Kong, SAR China $0.790B 20.69
Embecta (EMBC) United States $0.778B 5.18
SBC Medicals (SBC) United States $0.677B 0.00
Agilon Health (AGL) United States $0.655B 0.00
InnovAge Holding (INNV) United States $0.647B 0.00
Auna S.A (AUNA) Luxembourg $0.536B 0.00
Sonida Senior Living (SNDA) United States $0.425B 0.00
DocGo (DCGO) United States $0.410B 15.46
Enhabit (EHAB) United States $0.366B 31.61
COMPASS Pathways (CMPS) United Kingdom $0.326B 0.00
LifeMD (LFMD) United States $0.241B 0.00
ModivCare (MODV) United States $0.223B 12.09
Sera Prognostics (SERA) United States $0.209B 0.00
Beauty Health (SKIN) United States $0.200B 0.00
Biodesix (BDSX) United States $0.180B 0.00
Nutex Health (NUTX) United States $0.156B 0.00
Ascend Wellness Holdings (AAWH) United States $0.100B 0.00
So-Young (SY) China $0.092B 22.25
MultiPlan (MPLN) United States $0.084B 0.00
Singular Genomics Systems (OMIC) United States $0.054B 0.00
OncoCyte (OCX) United States $0.043B 0.00
NeueHealth (NEUE) United States $0.041B 1.08
Co-Diagnostics (CODX) United States $0.034B 0.00
Pheton Holdings (PTHL) China $0.030B 0.00
IceCure Medical (ICCM) Israel $0.028B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.020B 0.00
Oncology Institute (TOI) United States $0.014B 0.00
SeaStar Medical Holding (ICU) United States $0.009B 0.00
XWELL (XWEL) United States $0.008B 0.00
Intelligent Bio Solutions (INBS) United States $0.006B 0.00
BioNexus Gene Lab (BGLC) $0.005B 0.00
KindlyMD (KDLY) United States $0.005B 0.00
ISpecimen (ISPC) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.002B 0.00
Aclarion (ACON) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.001B 0.00